Nyxoah SA (NYXH) Stock Forecast & Price Target

Nyxoah is viewed positively because its U.S. launch is still building momentum, with 3Q26 adding 80 trained surgeons, 53 activated accounts, and 447 patients under active prior authorization, while the U.S. business still grew 29% sequentially. The lower 2026 revenue guide appears tied to slower U.S. account ramp timing rather than weaker demand, since International was in line and Q2 net revenue of €7.7M matched pre-announced results while FY26 revenue guidance of €36-40M was reaffirmed. Fundamentals are further supported by the CCC expansion path, as ACCCESS hit its co-primary endpoint with a 77.2% 12-month AHI responder rate and zero device- or procedure-related SAEs, and the PMA supplement filing under Breakthrough Device Designation keeps label expansion and reimbursement catalysts on track.

Nyxoah is facing a weaker-than-expected near-term commercial trajectory, as 3Q26 net revenue of €9.2M missed FactSet consensus of €9.9M and full-year 2026 guidance was cut to €33-35M from €36-40M, signaling softer execution than previously anticipated. The company’s outlook is further pressured by adoption risk as it competes in hypoglossal nerve stimulation against Inspire Medical Systems, while its cash-burn-heavy model raises the risk that it may not secure additional capital on favorable terms. Regulatory uncertainty around the ACCCESS study adds another layer of risk, and even with projected 2027E revenue of $73.3M and 2028E revenue of $117M, the stock remains exposed to execution and financing concerns despite a discount to peers.